Huningue, France – 26/11/2024
Firalis, a biotechnology SME specializing in in-vitro diagnostics based on biomarker detection, announces today that it has secured over 1.284 M€ in funding from Bpifrance, through the France 2030 plan. This significant contribution, granted under the “Industrialisation et Capacités Santé” call for projects, will enable Firalis to establish an autonomous bioproduction facility in Huningue, France. The center will focus on the production of cutting-edge diagnostic and therapeutic biological tools for currently incurable diseases, including heart failure and Alzheimer’s disease.
This financing, part of a total 7.2 M€ project, marks a pivotal moment in Firalis’s growth and will allow the company to significantly advance its ambitious vision of providing innovative, sustainable healthcare solutions. The new facility will not only strengthen Firalis’s internal capabilities but also support third-party diagnostic candidates by offering CE-IVDR certification services in compliance with the latest European regulatory standards. Designed with a low-carbon footprint, the center embodies Firalis’s commitment to eco-friendly and sustainable bioproduction.
“Securing this funding from the State via France 2030 with the invaluable support of Bpifrance is a crucial step forward for Firalis and for advancing the future of precision medicine,” said Pr. Hueseyin Firat, CEO and Founder of Firalis. “This investment will allow us to scale up our production and bring innovative diagnostic and therapeutic solutions to patients suffering from currently underserved diseases. We are deeply grateful to the State and Bpifrance for their trust in our project, which will also contribute to the development of the French healthcare ecosystem and the creation of over a hundred new jobs by 2029.”
Scheduled to be fully operational by 2026, the new Firalis facility in Huningue will strengthen France’s position in the global in-vitro diagnostics market. This project aligns perfectly with France 2030’s objectives to build a more resilient and innovative healthcare sector.
Firalis extends its sincere thanks to Bpifrance and the French State for their continued support and for helping make this ambitious project a reality.